Nuo Therapeutics, Inc. (AURX) Form 10-Q — May 14, 2026
Nuo Therapeutics reported Q1 2026 revenue of $1.3 million, a 153% year-over-year increase driven by expanded Aurix product sales and a new private-label distribution agreement with Smith+Nephew. Despite the top-line growth, the company posted a net loss of $618,000 and consumed $784,000 in operating cash, leaving it with only $300,000 in cash reserves. The filing includes explicit going-concern language, stating that current resources are insufficient to support operations for the next 12 months.
Key figures
- Revenue
- 1302115
- Debt Amount
- 1000000
- Revenue Yoy
- 153%
- Cash Position
- 300000
- Interest Rate
- 10%
- Maturity Date
- 2028-12-31
- Shares Outstanding
- 48408728
- Gross profit
- 849727
- Warrants issued
- 282332
- Operating expenses
- 1296193
- Accumulated deficit
- 35390628
- Warrant exercise price
- 1.5
- Smith nephew upfront fee
- 1500000
- Smith nephew milestone fees
- 750000
Price after filing
Close on the filing date to close N calendar days later (from $1.35). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.